CTRI/2019/03/017991尚未招募1 期
To Evaluate the Safety, Tolerability and Sensory Evaluation of HQMZ111831 in Healthy Female Volunteers: Randomized Open Label, Two Arm Clinical Study - Quista_M
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Healthy Adult female volunteers.
- •2)Aged >=18 to <= 45 years.
- •3)Subjects willing to sign the informed consent.
- •4)Subjects to be refrained to take any other similar kind of intervention during the study period.
排除标准
- •1)Subjects clinically diagnosed with any clinically significant systemic disorder.
- •2)Subjects on any other nutritional supplements.
- •3)A known history or present condition of allergic response to pharmaceutical products its components or ingredients in the test products.
- •4)Genetic and Endocrinal disorders.
- •5)Has participated in a similar clinical investigation in the past four weeks.
- •6)Subjectâ??s parents who refused to sign informed consent.
研究者
相似试验
尚未招募
1 期
Phase I safety study of HQAP061801 in Healthy Adult VolunteersCTRI/2019/03/017972The Himalaya Drug Company
招募中
1 期
â??Safety study of Quista - Isolate in Healthy Adult VolunteersCTRI/2020/09/028141The Himalaya Drug Company
撤回
4 期
Evaluation of weekly tafenoquine antimalarial prophylaxis in Vietnam People’s Army personnel in South SudaInfection - Other infectious diseasesMalariaACTRN12622000272796Australian Defence Force Malaria and Infectious Disease Institute63
已完成
2 期
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy VolunteersA (Healthy Volunteers)Healthy CoronavirusY59.9LBCTR2020113522Inovio Pharmaceuticals, Inc.542
已完成
2 期
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT2080223117Eisai Co., Ltd.800